Transforming The Economics Of AAV Manufacture While Optimizing Quality With dbDNA™

Review how enzymatically produced linear, closed double‑stranded DNA—known as dbDNA—is redefining the technical and economic landscape of AAV vector manufacturing. Traditional plasmid DNA introduces challenges including bacterial impurities, antibiotic‑resistance genes, endotoxins, long production timelines, and high costs. In contrast, dbDNA is generated through a rapid, bacteria‑free enzymatic process that delivers high‑fidelity DNA without unwanted sequences, simplifying purification and improving safety. Its minimal, linear design reduces the DNA needed for transfection by more than 40%, cuts transfection reagent use, and consistently enhances AAV packaging efficiency, producing a higher percentage of full capsids. These improvements increase functional vector yield, lower cost of goods, and streamline downstream purification.

dbDNA is highly scalable, with small‑volume production equivalent to large fermentation runs, and offers much faster turnaround times than plasmid DNA. The technology is already supporting clinical-stage programs and benefiting from a favorable regulatory outlook, positioning it as a next‑generation solution for more efficient AAV manufacturing.